The Company enters into contracts in the normal course of business with contract research organizations in preparation for clinical trials, professional consultants for expert advice and other vendor…
The Company enters into contracts in the normal course of business with contract research organizations in preparation for clinical trials, professional consultants for expert advice and other vendor…
expenses incurred in connection with the discovery and preclinical development of our product candidates, including under agreements with third parties, such as consultants and CROs
the cost of manufacturing compounds for use in our preclinical studies, including under agreements with third parties, such as consultants and third-party manufacturers
Tyra Biosciences, Inc. Customers
No clients on recordNo downstream customers found in our database for Tyra Biosciences, Inc..
Tyra Biosciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TYRA-DEBT-13181
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
TYRA-DEBT
Debt stack $5.7M
90%
Market cache reports total debt of $5.7M.
TYRA-DEBT-13180
Warrants outstanding: 0.001
90%
xbrl warrant detail from xbrl 2024-10-18.
Tyra Biosciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Tyra Biosciences, Inc..
Tyra Biosciences, Inc. Ownership
Holder
Name
Confidence
Evidence
TYRA-OWNER-RA-CAPITAL-MANAGEMENT-L-P
RA CAPITAL MANAGEMENT, L.P.
90%
13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 164 tracked holders.
Tyra Biosciences, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
